190 related articles for article (PubMed ID: 34115385)
1. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Hoch M; Sato M; Zack J; Quinlan M; Sengupta T; Allepuz A; Aimone P; Hourcade-Potelleret F
J Clin Pharmacol; 2021 Nov; 61(11):1454-1465. PubMed ID: 34115385
[TBL] [Abstract][Full Text] [Related]
2. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Hoch M; Sengupta T; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jun; 15(6):1406-1416. PubMed ID: 35293131
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Hoch M; Zack J; Quinlan M; Huth F; Forte S; Dodd S; Aimone P; Hourcade-Potelleret F
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):207-219. PubMed ID: 34609077
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
8. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
11. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
13. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
14. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Tran P; Hanna I; Eggimann FK; Schoepfer J; Ray T; Zhu B; Wang L; Priess P; Tian X; Hourcade-Potelleret F; Einolf HJ
Xenobiotica; 2020 Feb; 50(2):150-169. PubMed ID: 31006307
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
18. Relative Bioavailability and Food Effect of Asciminib Pediatric Mini-tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants.
Hoch M; Bebrevska L; Singh N; Hourcade-Potelleret F
Clin Pharmacol Drug Dev; 2023 May; 12(5):484-492. PubMed ID: 36622274
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
Jogiraju V; Weber E; Hindman J; West S; Ling J; Rhee M; Girish S; Palaparthy R; Singh R
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0134423. PubMed ID: 38456707
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]